[Advances in measurements and standardization of plasma phosphorylated tau217 as a biomarker for Alzheimer's disease].

With the approval of targeted drugs for modification therapy of Alzheimer's disease, the role of blood markers in the diagnosis and treatment of Alzheimer's disease is becoming more and more important. The economical and easily accessible plasma phosphorylated tau217 (p-tau217) is one of the most promising biomarkers for clinical application. Since it was first found in 2020, it has attracted wide attention in just a few years, rapidly becoming a research hotspot in this field, and is adopted as one of the core diagnostic biomarkers. This article reviewed the clinical measurements of plasma p-tau217 and the standardization of sample processing.